Soligenix (SNGX) Share-based Compensation (2010 - 2026)
Soligenix's (SNGX) quarterly Share-based Compensation came in at $10002.0 in Q1 2026, down 84.27% YoY from $63599.0 in Q1 2025, and up 112.73% on a QoQ basis from -$78559.0 in Q3 2025.
Soligenix (SNGX) Share-based Compensation (2010 - 2026) Analysis & Trends
Soligenix (SNGX) has 17 years of Share-based Compensation data on file, last reported at $10002.0 in Q1 2026.
- Quarterly Share-based Compensation fell 84.27% year-over-year to $10002.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$140744.0 (down 195.35% YoY) and the FY2025 annual result came in at $76600.0, down 76.77% from the prior year.
- Share-based Compensation grew to $10002.0 in Q1 2026, from -$78559.0 in the prior quarter.
- In the past five years, Share-based Compensation ranged from a high of $155547.0 in Q4 2024 to a low of -$78559.0 in Q3 2025.
- A 5-year average of $42896.7 and a median of $65400.0 in 2023 frame the typical range for Share-based Compensation.
- Annual changes were most pronounced in 2022 — Share-based Compensation surged 155.74% — and 2024, when it plunged 154.15%.
- Tracing SNGX's Share-based Compensation over 5 years: stood at $126890.0 in 2022, then plunged by 48.46% to $65400.0 in 2023, then surged by 137.84% to $155547.0 in 2024, then tumbled by 150.5% to -$78559.0 in 2025, then surged by 112.73% to $10002.0 in 2026.
- The last three Share-based Compensation figures came in at $10002.0 (Q1 2026), -$78559.0 (Q3 2025), and -$72187.0 (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Stock Comp. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 140.39 Bn | 132.54 Bn | 2.84 Bn | 108.10 Mn |
| 2 | Regeneron Pharmaceuticals | 86.47 Bn | 78.47 Bn | 3.93 Bn | 243.00 Mn |
| 3 | Argenx Se | 65.25 Bn | 60.07 Bn | 1.37 Bn | - |
| 4 | Moderna | 61.79 Bn | 56.66 Bn | 52.00 Mn | 120.00 Mn |
| 5 | BeOne Medicines | 42.27 Bn | 37.17 Bn | 1.53 Bn | 137.41 Mn |
| 6 | Alnylam Pharmaceuticals | 31.17 Bn | 27.86 Bn | 992.69 Mn | 86.63 Mn |
| 7 | BioNTech SE | 28.61 Bn | 10.22 Bn | 668.28 Mn | 28.05 Mn |
| 8 | Insmed | 27.44 Bn | 26.28 Bn | 358.27 Mn | 41.25 Mn |
| 9 | Royalty Pharma | 27.30 Bn | 26.46 Bn | - | - |
| 10 | Soligenix | 6.26 Mn | 6.26 Mn | - | -115,972.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -115,972.00 |
| Jun 30, 2026 | -115,972.00 |
| Mar 31, 2026 | 10,002.00 |
| Mar 31, 2026 | 10,002.00 |
| Sep 30, 2025 | -78,559.00 |
| Sep 30, 2025 | -78,559.00 |
| Jun 30, 2025 | -72,187.00 |
| Jun 30, 2025 | -72,187.00 |
| Mar 31, 2025 | 63,599.00 |
| Mar 31, 2025 | 63,599.00 |
| Dec 31, 2024 | 155,547.00 |
| Dec 31, 2024 | 155,547.00 |
| Sep 30, 2024 | -35,416.00 |
| Sep 30, 2024 | -35,416.00 |
| Jun 30, 2024 | -36,118.00 |
| Jun 30, 2024 | -36,118.00 |
| Mar 31, 2024 | 59,961.00 |
| Mar 31, 2024 | 59,961.00 |
| Sep 30, 2023 | 65,400.00 |
| Sep 30, 2023 | 65,400.00 |